{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:41:59Z","timestamp":1775886119062,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients vs. non-COVID-19 patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019.<\/jats:p><jats:p><jats:bold>METHODS:<\/jats:bold> All ALSs that reflected potential SADRs including neutropenia, pancytopenia, thrombocytopenia, anemia, eosinophilia, leukocytes in cerebrospinal fluid, hepatitis, pancreatitis, acute kidney injury, rhabdomyolysis, and hyponatremia were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 patients.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> The incidence rate of SADRs detected in the COVID-19 patients was 760.63 (95% CI 707.89\u2013816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-COVID-19 patients (160.15 per 10,000 patients, 95% CI 137.09\u2013186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53\u2013154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine\/hydroxychloroquine (6.91%).<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is recommended when using medications for COVID-19 patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events.<\/jats:p>","DOI":"10.3389\/fphar.2020.602841","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T08:33:42Z","timestamp":1606984422000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data"],"prefix":"10.3389","volume":"11","author":[{"given":"Elena","family":"Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Urroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gonz\u00e1lez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mart\u00edn-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Vill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Seco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio J.","family":"Carcas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1515\/dx-2020-0046","article-title":"Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States","volume":"7","author":"Aggarwal","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Evaluaci\u00f3n de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Espa\u00f1ol de Farmacovigilancia","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Cl\u00ednica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/2050640620924157","article-title":"Liver injury in COVID-19: the current evidence","volume":"8","author":"Alqahtani","year":"2020","journal-title":"United European Gastroenterol. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/nejmra066469","article-title":"Drug-induced Immune thrombocytopenia","volume":"357","author":"Aster","year":"","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40264-016-0489-7","article-title":"Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France","volume":"40","author":"Auffret","year":"2017","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bcp.12222","article-title":"Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital","volume":"77","author":"Bellis","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/jcm9061733","article-title":"A cohort of patients with COVID-19 in a major teaching hospital in Europe","volume":"9","author":"Borobia","year":"2020","journal-title":"J. Clin. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11096-014-0054-3","article-title":"Drug-induced anaemia: a decade review of reporting to the Italian Pharmacovigilance data-base","volume":"37","author":"Carnovale","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"B11","article-title":"Coronavirus disease (COVID-19). Spain: ministery of health","author":"Center for Coordination of Health Alerts and Emergencies","year":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B13","volume-title":"COVID-19: Current situation in the Community of Madrid","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1515\/cclm-2020-0573","article-title":"Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation","volume":"58","author":"Favaloro","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s1386-5056(99)00020-9","article-title":"Detecting adverse drug reactions to improve patient outcomes","volume":"55","author":"Hannan","year":"1999","journal-title":"Int. J. Med. Inf."},{"key":"B17","volume-title":"ICH guideline on E2D postapproval safety data management: definitions and standards for expedited reporting","year":"2004"},{"key":"B18","volume-title":"Organic law 3\/2018, december 5, 2018, protection of personal data and guarantee of digital rights (BOE n\u00fam. 294, 2017, 119788\u201311985)","year":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/clpt.2009.185","article-title":"A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients","volume":"87","author":"Ramirez","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcp.13096","article-title":"Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital","volume":"83","author":"Ram\u00edrez","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/cpt.1562","article-title":"Severe hyponatremia is often drug induced: 10\u2010year results of a prospective pharmacovigilance program","volume":"106","author":"Ram\u00edrez","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.1986.03380130077032","article-title":"Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study","volume":"256","year":"1986","journal-title":"J. Am. Med. Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"B24","year":""},{"key":"B25","unstructured":""},{"key":"B26","year":""},{"key":"B27","unstructured":""},{"key":"B28","unstructured":""},{"key":"B29","unstructured":""},{"key":"B30","unstructured":""},{"key":"B31","unstructured":""},{"key":"B32","unstructured":""},{"key":"B33","unstructured":""},{"key":"B34","unstructured":""},{"key":"B35","unstructured":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.1866","article-title":"Incidence of adverse drug reactions in COVID\u201019 patients in China: an active monitoring study by hospital pharmacovigilance system","volume":"108","author":"Sun","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"","journal-title":"J. Thromb. Haemostasis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"","journal-title":"BMJ"},{"key":"B39","unstructured":"Clinical management of COVID-19: hospital care"},{"key":"B40","unstructured":"Emergency management of COVID-19"},{"key":"B41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/14740338.2016.1221401","article-title":"Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study","volume":"15","author":"Viola","year":"2016","journal-title":"Expet Opin. Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drudis.2018.06.006","article-title":"Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management","volume":"24","author":"Wen","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/1389200218666171108154419","article-title":"Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies","volume":"19","author":"Wu","year":"2018","journal-title":"Cdm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/fcp.12349","article-title":"Drug-induced aseptic meningitis: a mini-review","volume":"32","author":"Yelehe-Okouma","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jth.14859","article-title":"D\u2010dimer levels on admission to predict in\u2010hospital mortality in patients with Covid\u201019","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Thromb. Haemostasis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajg.2019.11.005","article-title":"Drug-induced pancreatitis: an update","volume":"20","author":"Zheng","year":"2019","journal-title":"Arab J. Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.602841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T08:33:51Z","timestamp":1606984431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.602841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":47,"alternative-id":["10.3389\/fphar.2020.602841"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.602841","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"article-number":"602841"}}